Brainomix, an Oxford-based AI-powered MedTech solutions company, announced that it closed a £16 million ($21.2M) in Series B financing round, to fund its expansion into new markets and new therapeutic indications, including lung fibrosis and cancer.
The round was co-led by existing investors Boehringer Ingelheim Venture Fund (BIVF) and Parkwalk Advisors, along with new investor, Tencent Holdings, and included participation from Oxford University Innovation Fund (OUIF).
This investment will build on the proven success of the company's tech platform in stroke and enable value-generating pharmaceutical partnerships to improve clinical trial success, foster broader adoption of existing therapies in the new indications, and improve patient outcomes.
The funds will also enable the company to drive into new therapeutic areas beyond stroke by developing novel imaging biomarkers for better treatment of lung fibrosis and cancer, which have similar unmet needs to stroke.
Company: Brainomix Limited
Round: Series B
Funding Month: December 2021
Lead Investors: Boehringer Ingelheim Venture Fund (BIVF) and Parkwalk Advisors
Additional Investors: Tencent Holdings and Oxford University Innovation Fund (OUIF)
Company Website: https://www.brainomix.com/
Software Category: AI-powered MedTech solutions
About the Company: Brainomix is an Oxford-based company specializing in the creation of AI-enabled software solutions to enable precision medicine for better treatment decisions in stroke and certain lung conditions. Since launching as a spin-out from the University of Oxford in 2010, it has developed award-winning, AI-powered imaging biomarkers, and software solutions, assisting physicians across the world to make better life-saving decisions. Its e-Stroke platform provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients.